Cytokinetics, Incorporated
Price Action
Technical Summary
STAGE 2 UPTRENDCytokinetics, Incorporated is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is leading (RS Rating: 84), indicating clear outperformance against the broad market. Earnings contraction of 23% provides fundamental context to the price action. Investors should exercise caution due to high volatility (61% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $74.80 | +16.66% | ABOVE |
| 50 SMA | $72.87 | +19.74% | ABOVE |
| 100 SMA | $68.40 | +27.58% | ABOVE |
| 150 SMA | $66.88 | +30.48% | ABOVE |
| 200 SMA | $64.63 | +35.01% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is CYTK in an uptrend right now?
CYTK has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, CYTK is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.
Is CYTK overbought or oversold?
CYTK's RSI (14) is 69. The stock is in neutral territory, neither overbought nor oversold.
Is CYTK outperforming the market?
CYTK has a Relative Strength (RS) Rating of 84 out of 99. Yes, CYTK is a market leader, outperforming 84% of all stocks over the past 12 months.
Where is CYTK in its 52-week range?
CYTK is trading at $87.26, which is 100% of its 52-week high ($87.35) and 100% above its 52-week low ($32.66).
How volatile is CYTK?
CYTK has a Beta of 0.76 and 52-week volatility of 61%. It's less volatile than the S&P 500 - generally more stable.